Evoke Pharma Inc
DelistedCIK 1403708fmd_1NARF3WG4VTYJ35AAXPTRZCK6QManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2025, 59 periods
Latest annual · FY2024
Millions- Total revenues
- 10
- Operating income
- (5)
- Net income
- (5)
Latest quarter · Q3 FY2025
Millions- Total revenues
- 4
- Operating income
- (1)
- Net income
- (1)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- +85.0%
- Revenue, 5 yearsFY2019 to FY2024
- n/m
- Net income, 5 yearsFY2019 to FY2024
- n/m
Evoke Pharma Inc financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | $10.2 million | $5.2 million | +97.8% | 10-K 2025-03-13 · proof |
| Operating income | -$5.2 million | -$7.4 million | 10-K 2025-03-13 · proof | |
| Net income | -$5.4 million | -$7.8 million | 10-K 2025-03-13 · proof | |
| Cash from operating activities | -$5.5 million | -$5 million | 10-K 2025-03-13 · proof | |
| Total assets | $17.5 million | $7.1 million | +147.8% | 10-K 2025-03-13 · proof |
| Total liabilities | $10.5 million | $9.6 million | +8.6% | 10-K 2025-03-13 · proof |
| Cash and cash equivalents | $13.6 million | $4.7 million | +186.9% | 10-K 2025-03-13 · proof |
- What was Evoke Pharma Inc's revenue in fiscal 2024?
- Evoke Pharma Inc reported revenue of $10.2 million for fiscal 2024 (the year ended Dec 31, 2024), against $5.2 million the year before (+97.8%). Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What was Evoke Pharma Inc's operating income in fiscal 2024?
- Evoke Pharma Inc reported operating income of -$5.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$7.4 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What was Evoke Pharma Inc's net income in fiscal 2024?
- Evoke Pharma Inc reported net income of -$5.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$7.8 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What was Evoke Pharma Inc's cash from operating activities in fiscal 2024?
- Evoke Pharma Inc reported cash from operating activities of -$5.5 million for fiscal 2024 (the year ended Dec 31, 2024), against -$5 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What are Evoke Pharma Inc's total assets?
- As of Dec 31, 2024, Evoke Pharma Inc reported total assets of $17.5 million, against $7.1 million a year earlier (+147.8%). Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What are Evoke Pharma Inc's total liabilities?
- As of Dec 31, 2024, Evoke Pharma Inc reported total liabilities of $10.5 million, against $9.6 million a year earlier (+8.6%). Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What are Evoke Pharma Inc's cash and cash equivalents?
- As of Dec 31, 2024, Evoke Pharma Inc reported cash and cash equivalents of $13.6 million, against $4.7 million a year earlier (+186.9%). Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1403708&period_type=annual&limit=5"Information only, not investment advice.